Trial intelligence / Profile preview

Phase 3 open-label pegylated interferon lambda-1a + ribavirin + daclatasvir study in treatment-naive chronic hepatitis C with HIV co-infection

2012-003280-22Phase 3Completed

Sponsor

Bristol Myers Squibb

Start

Jun 2013

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Countries

1